{"id":240392,"date":"2026-09-10T11:32:04","date_gmt":"2026-09-10T06:02:04","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=240392"},"modified":"2026-09-10T11:32:04","modified_gmt":"2026-09-10T06:02:04","slug":"is-dishman-carbogen-amcis-a-good-buy-after-q1-fy27-results","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/is-dishman-carbogen-amcis-a-good-buy-after-q1-fy27-results\/","title":{"rendered":"Is Dishman Carbogen Amcis a Good Buy After Its Q1 FY27 Results?"},"content":{"rendered":"

Dishman Carbogen Amcis share price around Rs 170. 47.1% below 52-week high of Rs 322. Q1 FY27 revenue Rs 696 crore, down 5.0% YoY. loss of Rs 58 crore.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Dishman Carbogen Amcis swung to a net loss of Rs 58 crore in Q1 FY27, as revenue also fell 5.0% to Rs 696 crore. This is a meaningful shift from the year-ago quarter, and the Dishman Carbogen Amcis share price should be evaluated against this profitability reset rather than the topline trend alone before calling it a good buy.<\/p>\n<\/p><\/div>\n

The Dishman Carbogen Amcis share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Dishman Carbogen Amcis is a contract research and manufacturing (CRAMS) company serving global pharmaceutical clients, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.<\/p>\n

Revenue for the quarter came in at Rs 696 crore, down 5.0% year on year, while the company reported a net loss of Rs 58 crore. That combination of numbers is exactly what this article breaks down, along with what it means for the Dishman Carbogen Amcis share price from here.<\/p>\n

This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Dishman Carbogen Amcis share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n